Status:
COMPLETED
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer. The study includes two groups of patients, those whos...
Eligibility Criteria
Inclusion
- Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV).
- Evidence of T790M mutation to enroll in Cohort A.
- Evidence of measurable disease by radiographic technique.
- Adequate organ function.
Exclusion
- Patients with T790M mutation who stopped any prior EGFR-directed therapy without evidence of disease progression.
- Symptomatic brain metastases.
- Uncontrolled or significant cardiovascular disease.
- Pregnant or breastfeeding.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT01858389
Start Date
July 1 2013
End Date
September 1 2015
Last Update
July 18 2017
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Tower Hematology Oncology Medical Group
Beverly Hills, California, United States, 90211
2
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States, 90048
3
Georgetown University Hospital-Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States, 20007
4
Georgetown University Medical Center Department of Pharmacy, Research
Washington D.C., District of Columbia, United States, 20007